156 related articles for article (PubMed ID: 24239626)
1. New aminopyrimidine derivatives as inhibitors of the TAM family.
Traoré T; Cavagnino A; Saettel N; Radvanyi F; Piguel S; Bernard-Pierrot I; Stoven V; Legraverend M
Eur J Med Chem; 2013; 70():789-801. PubMed ID: 24239626
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel type II c-Met inhibitors based on BMS-777607.
Zhang W; Ai J; Shi D; Peng X; Ji Y; Liu J; Geng M; Li Y
Eur J Med Chem; 2014 Jun; 80():254-66. PubMed ID: 24792774
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation.
Suárez RM; Chevot F; Cavagnino A; Saettel N; Radvanyi F; Piguel S; Bernard-Pierrot I; Stoven V; Legraverend M
Eur J Med Chem; 2013 Mar; 61():2-25. PubMed ID: 22749189
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and evaluation of highly selective pyridone-based class II MET inhibitors.
She N; Zhuo L; Jiang W; Zhu X; Wang J; Ming Z; Zhao X; Cong X; Huang W
Bioorg Med Chem Lett; 2014 Aug; 24(15):3351-5. PubMed ID: 24951334
[TBL] [Abstract][Full Text] [Related]
5. Novel 5-(benzyloxy)pyridin-2(1H)-one derivatives as potent c-Met inhibitors.
Zhang D; Ai J; Liang Z; Zhu W; Peng X; Chen X; Ji Y; Jiang H; Luo C; Geng M; Liu H
Bioorg Med Chem Lett; 2013 Apr; 23(8):2408-13. PubMed ID: 23474386
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.
Zhang D; Ai J; Liang Z; Li C; Peng X; Ji Y; Jiang H; Geng M; Luo C; Liu H
Bioorg Med Chem; 2012 Sep; 20(17):5169-80. PubMed ID: 22863529
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity.
El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
Bioorg Chem; 2018 Feb; 76():154-165. PubMed ID: 29175587
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
Williams DK; Chen XT; Tarby C; Kaltenbach R; Cai ZW; Tokarski JS; An Y; Sack JS; Wautlet B; Gullo-Brown J; Henley BJ; Jeyaseelan R; Kellar K; Manne V; Trainor GL; Lombardo LJ; Fargnoli J; Borzilleri RM
Bioorg Med Chem Lett; 2010 May; 20(9):2998-3002. PubMed ID: 20382527
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors.
Inoue S; Yamane Y; Tsukamoto S; Murai N; Azuma H; Nagao S; Nishibata K; Fukushima S; Ichikawa K; Nakagawa T; Hata Sugi N; Ito D; Kato Y; Goto A; Kakiuchi D; Ueno T; Matsui J; Matsushima T
Bioorg Med Chem Lett; 2021 Sep; 48():128247. PubMed ID: 34271070
[TBL] [Abstract][Full Text] [Related]
10. State-of-the-art of small molecule inhibitors of the TAM family: the point of view of the chemist.
Baladi T; Abet V; Piguel S
Eur J Med Chem; 2015 Nov; 105():220-37. PubMed ID: 26498569
[TBL] [Abstract][Full Text] [Related]
11. Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors.
Cai ZW; Wei D; Schroeder GM; Cornelius LA; Kim K; Chen XT; Schmidt RJ; Williams DK; Tokarski JS; An Y; Sack JS; Manne V; Kamath A; Zhang Y; Marathe P; Hunt JT; Lombardo LJ; Fargnoli J; Borzilleri RM
Bioorg Med Chem Lett; 2008 Jun; 18(11):3224-9. PubMed ID: 18479916
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel c-Met inhibitors bearing a 3-carboxyl piperidin-2-one scaffold.
Zhang W; Ai J; Shi D; Peng X; Ji Y; Liu J; Geng M; Li Y
Molecules; 2014 Feb; 19(2):2655-73. PubMed ID: 24566328
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of close analogs of LCRF-0004, a potent and selective RON receptor tyrosine kinase inhibitor.
Raeppel SL; Raeppel F; Therrien E
Bioorg Med Chem Lett; 2015 Jun; 25(12):2527-31. PubMed ID: 25953155
[TBL] [Abstract][Full Text] [Related]
14. Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors.
Dorsch D; Schadt O; Stieber F; Meyring M; Grädler U; Bladt F; Friese-Hamim M; Knühl C; Pehl U; Blaukat A
Bioorg Med Chem Lett; 2015 Apr; 25(7):1597-602. PubMed ID: 25736998
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of constrained analogs of LCRF-0004 as potent RON tyrosine kinase inhibitors.
Raeppel SL; Therrien E; Raeppel F
Bioorg Med Chem Lett; 2015 Sep; 25(17):3706-10. PubMed ID: 26112445
[TBL] [Abstract][Full Text] [Related]
16. [Development and biochemical characterization of EGFR/c-Met dual inhibitors].
Szokol B; Gyulavári P; Baska F; Ibolya K; Greff Z; Szántai KC; Zoltán O; Peták I; Axel U; Vantus T; Kéri G; Orfi L
Acta Pharm Hung; 2013; 83(4):121-33. PubMed ID: 24575658
[TBL] [Abstract][Full Text] [Related]
17. Discovery of aminopyridines substituted with benzoxazole as orally active c-Met kinase inhibitors.
Cho SY; Han SY; Ha JD; Ryu JW; Lee CO; Jung H; Kang NS; Kim HR; Koh JS; Lee J
Bioorg Med Chem Lett; 2010 Jul; 20(14):4223-7. PubMed ID: 20570511
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 3H-imidazo[4,5-b]pyridines as potent c-Met kinase inhibitors: design, synthesis, and biological evaluation.
Chen D; Wang Y; Ma Y; Xiong B; Ai J; Chen Y; Geng M; Shen J
ChemMedChem; 2012 Jun; 7(6):1057-70. PubMed ID: 22581753
[TBL] [Abstract][Full Text] [Related]
19. Studying the Binding Modes of Novel 2-Aminopyridine Derivatives as Effective and Selective c-Met Kinase Type 1 Inhibitors Using Molecular Modeling Approaches.
Ye Q; Fu C; Li J
Molecules; 2020 Dec; 26(1):. PubMed ID: 33374386
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors.
Baladi T; Aziz J; Dufour F; Abet V; Stoven V; Radvanyi F; Poyer F; Wu TD; Guerquin-Kern JL; Bernard-Pierrot I; Garrido SM; Piguel S
Bioorg Med Chem; 2018 Nov; 26(20):5510-5530. PubMed ID: 30309671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
